First-in-Human Phase 1 Study of GTA182, a Novel MTA-Cooperative PRMT5 Inhibitor, in Patients with MTAP-Deleted Advanced Non-Small Cell Lung Cancer

Conference: ESMO Asia, December 5-7 2025, Singapore

Clinical trial identification: CTR20243795

Abstract deadline: October 7, 2025

Please complete this form to provide us with all the information we need to submit the above abstract to ESMO Asia 2025. Without this information the submission cannot be completed.

Please submit the form via Email by clicking on Email below or Printing the form then send email to Corrine Zeng at lzeng@apeiron-bio.com.

ESMO 2025 Co-Author Form
1. Personal Information
2. Declaration of Competing Interests *

Authors are required to disclose any relevant financial conflict of interest in products or processes involved in their research, regardless of amount or value.